Novavax | NVAX - Sales Revenues

Stock Price
8.70
Daily Change
0.28 3.33%
Monthly
6.23%
Yearly
6.23%
Q1 Forecast
8.43

Novavax reported $84.51M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
Agenus USD 24.07M 2.77M Mar/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Geron USD 47.2M 1.8M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
MannKind USD 82.13M 5.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 678M 342M Dec/2025
Novartis USD 14.36B 478M Sep/2025
Novavax USD 84.51M 330.97M Sep/2024
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
TG Therapeutics USD 161.7M 20.6M Sep/2025